Thursday, September 18, 2025

Genentech and C3 AI Improve the Complex Biologics Manufacturing Process with AI

Related stories

Aisles Launches DREAM: AI-Driven Virtual Reality Evolution

Aisles has unveiled DREAM (Dynamic Reality Experience and Memory),...

TechSee Unveils Visual Remote Assistance with AI (VRAi) on Salesforce

TechSee, a global leader in visual customer assistance, announced...

Rendever and Lenovo Collaborate to Bring Virtual Reality Experiences to Carolina Caring Seniors

Rendever, the Boston-based company pioneering the future of aging...

Ansys 2024 R1 Reimagines the User Experience while Expanding Multiphysics Superiority Boosted by AI

The latest release from Ansys, 2024 R1, introduces an elevated user...

eXeX and Neurosurgeon Dr. Robert Masson Achieve World First Using Apple Vision Pro

eXeX™, a leader in artificial intelligence and mixed reality...
spot_imgspot_img

C3 AI, the Enterprise AI application software company, announced that Genentech, the medical biotechnology company, has selected C3 AI Reliability as the continued provider for AI-based predictive maintenance software on the company’s biologics manufacturing equipment.

The biotechnology company began using the AI application in 2021 to ensure centrifuges in the facility remained operational, with patients ultimately benefiting by receiving their medicines on time. Genentech uses this facility to manufacture biologics, a specific class of medicine that is extremely complex, time consuming, and resource intensive to develop and deliver to patients. These medicines help patients with some of the most difficult to treat diseases, from multiple sclerosis and macular degeneration to blood cancers such as lymphoma and leukemia.

Also Read: AION Labs Launches New Startup Leveraging Machine Learning for Molecular Glue Discovery

“We’re proud to partner with Genentech, a company well-known for delivering breakthrough medical innovations for patients, and support its efforts with a robust AI program that allows what is an involved manufacturing process to operate efficiently and ensure patients get the care they need on time,” said C3 AI CEO Thomas M. Siebel.

In 2022, Genentech expanded its use of C3 AI Reliability to new assets beyond centrifuges — scaling its AI footprint to around 200 pieces of equipment total. In addition to increasing the number of assets, the company also broadened employee training for the C3 AI Platform, on which the predictive maintenance application runs. The biotechnology company now has nearly 200 users — from data scientists to facility managers — who are trained on the C3 AI Platform and regularly use the AI application to evaluate equipment health and maintain manufacturing operations.

SOURCE: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img